威斯尼斯人官方网站8567vip(澳门)股份有限公司-MBA智库百科

中文

关于威斯尼斯人官方网站8567vip

研究与发展

产品及临床

产品管线

新闻与媒体

招贤纳士

招贤纳士

为了病患而驱动的创新

Patient-first cell therapy innovation

首页研究与发展科学论文

科学论文

2022

1. Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu ( 2022) Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy.
Cancer Cell 40, 674-693, June 13, 2022 DOI:https://doi.org/10.1016/j.ccell.2022.04.018

2. Shuhang Wang, Kun Chen, Yale Jiang, Guo Zhao, Caie Wang, Hong Fang, Qiyu Tang, Chao Sun, Liang Zhang, Haiyang Wu, Li-Feng Zhang, Ning Li Breaking boundaries: current progress of anticancer NK cell-based drug development
Drug Discovery Today, PII: S1359-6446(22)00429-9 DOI: https://doi.org/10.1016/j.drudis.2022.103436

Reference: DRUDIS 103436